中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

The Effect of Iron Deficiency Anemia During Pregnancy

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态已完成
赞助商
Assiut University

关键词

抽象

Iron deficiency anemia during pregnancy is a significant worldwide health problem, affecting 22% of pregnant women in industrialized countries and 52% in non-industrialized countries. Iron deficiency anemia during pregnancy is associated with increased maternal as well as fetal morbidity, including prematurity, low birth-weight and perinatal and infant loss. Therefore, routine iron supplementation during the second half of pregnancy has been recommended once daily. Others, however, support a selective iron supplementation only for women with iron deficiency anemia, in order to avoid the increased risk of haemoconcentration associated with routine iron supplementation. Unfortunately, compliance to either iron-supplementation programs, especially among pregnant women, is poor, due in part to the side effects associated with these preparations.
Currently, there are many iron preparations available containing different types of iron salts, including ferrous sulfate, ferrous fumarate, ferrous ascorbate but common adverse drug reactions found with these preparations are mainly gastrointestinal intolerance like nausea, vomiting, constipation, diarrhea, abdominal pain, while ferrous bis-glycinate (fully reacted chelated amino acid form of iron) rarely make complication.
Product resulting from the reaction of a metal ion from a soluble salt with amino acids to form coordinate covalent bonds, the resulting molecule is called as chelate and chemical bonding process is called chelation. Ferrous bis-glycinate is highly stable and totally nutritionally functional chelate it is an amino acid fully reacted chelate which is formed by the binding of two molecules of glycine to one Fe2+ atom.

日期

最后验证: 02/28/2018
首次提交: 10/26/2015
提交的预估入学人数: 10/26/2015
首次发布: 10/27/2015
上次提交的更新: 03/16/2018
最近更新发布: 03/19/2018
实际学习开始日期: 12/31/2015
预计主要完成日期: 06/30/2017
预计完成日期: 11/30/2017

状况或疾病

Iron Deficiency Anemia

干预/治疗

Drug: Ferrous bis-glycinate group

Drug: Ferrous glycine sulphate group

相 4

手臂组

干预/治疗
Active Comparator: Ferrous bis-glycinate group
The patients will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets) once daily for eight consecutive weeks.
Drug: Ferrous bis-glycinate group
Active Comparator: Ferrous glycine sulphate group
The patients will receive 567.6 mg of ferrous glycine sulphate capsules (Ferrosanol duodenale capsules, Schwarz) once daily for eight consecutive weeks.
Drug: Ferrous glycine sulphate group

资格标准

有资格学习的年龄 20 Years 至 20 Years
有资格学习的性别Female
接受健康志愿者
标准

Inclusion Criteria:

1. Singleton pregnancy.

2. Gestational age 14-18 weeks.

3. Mild to moderate anemia

4. No associated medical or obstetric complications.

5. Women not already receiving iron therapy.

6. Women accepted to participate in the study.

Exclusion Criteria:

1. Multiple pregnancy

2. Severe anemia

3. Iron hypersensitivity.

4. Liver diseases.

5. Women refuse to participate in the study.

结果

主要结果指标

1. the rate of increase of Hemoglobin level [8 weeks]

difference in hemoglobin concentrations before and after treatment

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge